A TWO PART SEAMLESS MULTI-CENTER RANDOMIZED PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS.
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs RG 7916 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SUNFISH
- Sponsors Roche
- 01 Jul 2017 According to a PTC Therapeutics media release, preliminary data from an early analysis of Part 1 of this trial were presented at CureSMA Conference.
- 01 Jul 2017 Preliminary data from this trial published in a PTC Therapeutics Media Release.
- 08 May 2017 According to a PTC Therapeutics media release, data from the first part of this study are expected to be presented at scientific meetings later this year (2017) and early 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History